Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Kane Biotech ( (TSE:KNE) ).
Kane Biotech Inc. has announced an upcoming investor webinar to outline its strategic plans for 2025, following significant achievements in 2024, including increased manufacturing and distribution of its revyve™ Antimicrobial Wound Gel, and the acquisition of FB Dermatology to enhance its market presence in Europe, Australia, and New Zealand. The company also revealed a six-month service agreement with Outside The Box Capital to enhance its marketing efforts through digital channels, aiming to elevate its visibility in the financial community.
More about Kane Biotech
Kane Biotech Inc. is a biotechnology company specializing in the research, development, and commercialization of technologies and products aimed at preventing and removing microbial biofilms. The company holds a diverse portfolio of biotechnologies, intellectual property, and various products such as DispersinB®, coactiv+™, and revyve™, developed through its own biofilm research and acquisitions from leading research institutions. Kane is publicly traded on the TSX Venture Exchange and the OTCQB Venture Market.
YTD Price Performance: -4.55%
Average Trading Volume: 86,951
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$14.44M
Find detailed analytics on KNE stock on TipRanks’ Stock Analysis page.
